Xcout IntelCalidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Subscribe to see Calidi Biotherapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Calidi Biotherapeutics, Inc. at a glance
Calidi Biotherapeutics, Inc. is a biotech company headquartered in San Diego, United States. It is publicly listed (CLDI) with a market capitalisation of $755,117. Xcout tracks 19 named people at Calidi Biotherapeutics, Inc., including Eric E. Poma (Chief Executive Officer & Director).
Calidi Biotherapeutics, Inc. leadership
- Eric E. PomaChief Executive Officer & Director
- Eric Poma, Ph.D.Chief Executive Officer and Director
- Andrew C. JacksonChief Financial Officer & Corporate Secretary
- Andrew JacksonChief Financial Officer
- Antonio F. Santidrian, PharmD, Ph.D.Chief Scientific Officer and Head of Technical Operations
- Antonio Fernandez SantidrianHead of Technical Operations & Chief Scientific Officer
13 more named people on record for Calidi Biotherapeutics, Inc., with roles, board committees and tenure — see the full roster →
Calidi Biotherapeutics, Inc. competitors
A few of Calidi Biotherapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
IconOVir Bio, Inc. is a preclinical-stage biotechnology company headquartered in New York, United States, with a primary location in San Diego, California. Established in 2020, the venture-backed company is dedicated to pioneering novel oncolytic viral therapies to cure cancer and restore life to patients.
CVBio is a biotechnology company that develops virus-driven immunotherapies, specifically utilizing engineered oncolytic adenoviruses to target and destroy resistant cancer cells. The company's platform is designed to treat aggressive cancers, including adult and pediatric brain tumors, by selectively infecting tumor cells and eliciting an anti-tumor immune response.
Kadimastem Ltd. is a clinical-stage cell therapy company headquartered in Ness Ziona, Israel, focused on developing advanced cell-based therapeutic treatments.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.
BioEclipse Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in California. The company is focused on researching and developing a novel generation of targeted immunotherapies and treatments for oncology.
Get Calidi Biotherapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Calidi Biotherapeutics, Inc. in Xcout Intel
- 19 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access